What is KeyCorp’s Estimate for Repligen Q2 Earnings?

Repligen Corporation (NASDAQ:RGEN) – Analysts at KeyCorp issued their Q2 2026 earnings estimates for Repligen in a research note issued to investors on Monday, June 1st. KeyCorp analyst P. Knight forecasts that the biotechnology company will post earnings of $0.49 per share for the quarter. KeyCorp currently has a “Overweight” rating on the stock. The consensus estimate for Repligen’s current full-year earnings is $1.99 per share. KeyCorp also issued estimates for Repligen’s Q3 2026 earnings at $0.47 EPS, Q4 2026 earnings at $0.57 EPS and FY2026 earnings at $2.00 EPS.

Several other analysts also recently weighed in on the stock. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen downgraded shares of Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Jefferies Financial Group reaffirmed a “hold” rating and set a $142.00 price target on shares of Repligen in a research note on Tuesday, May 5th. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Finally, Barclays boosted their price objective on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and an average price target of $164.64.

Repligen Stock Performance

Repligen stock opened at $130.76 on Thursday. The company has a 50 day moving average price of $119.67 and a 200-day moving average price of $138.16. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20. Repligen has a fifty-two week low of $100.99 and a fifty-two week high of $175.77. The company has a market capitalization of $7.38 billion, a PE ratio of 145.29, a P/E/G ratio of 2.51 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same quarter in the previous year, the firm posted $0.39 earnings per share. The company’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS.

Hedge Funds Weigh In On Repligen

A number of large investors have recently bought and sold shares of the business. NewEdge Wealth LLC raised its stake in Repligen by 5.3% in the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after buying an additional 75 shares in the last quarter. UMB Bank n.a. grew its holdings in Repligen by 13.8% in the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 92 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in Repligen by 0.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after purchasing an additional 100 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in Repligen by 5.3% in the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 101 shares during the last quarter. Finally, Itau Unibanco Holding S.A. grew its holdings in Repligen by 38.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.